New vaccine may transfer HIV infections in the category of non-hazardous
Spanish researchers tested the vaccine MVA-B and found that it initiated the immune response to HIV in 92% of cases, writes The Telegraph. Professor Mariano Esteban, head of the project at the National biotechnical center in Madrid, states: vaccine-body begins to recognize HIV.
Known that the vaccine contains four genes of the virus, which stimulate T and B lymphocytes – types of white blood cells. Different cells are programmed to deal with different types of pathogens. HIV easily they can not win, so lymphocytes need to "train". B cells produce antibodies that attack viruses before they infect cells. But the T-cells identify and destroy infected cells.
Proposed vaccine allowed in two-thirds of volunteers to develop targeted HIV antibodies after 11 months after vaccination. More than 30% developed a type of T-cells against HIV, called CD4. And the rest is another type of cells – CD8. Although the immune response and has been called, it does not mean that the vaccine protects against the virus. Verify its effectiveness, scientists gather in people with HIV, it might be able to reduce the concentration of virus in the blood.